Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens. New β-lactam/β-lactamase inhibitor combinations...

Full description

Bibliographic Details
Main Authors: Pasquale Sansone, Luca Gregorio Giaccari, Giusy Di Flumeri, Maria Caterina Pace, Vincenzo Pota, Francesco Coppolino, Simona Brunetti, Caterina Aurilio
Format: Article
Language:English
Published: MDPI AG 2024-05-01
Series:Life
Subjects:
imipenem/cilastatin/relebactam
recarbrio
complicated urinary tract infections
complicated intra-abdominal infections
hospital-acquired pneumonia
ventilator-associated pneumonia
Online Access:https://www.mdpi.com/2075-1729/14/5/614

Internet

https://www.mdpi.com/2075-1729/14/5/614

Similar Items